FDA approves Vanda's Bysanti for bipolar disorder and schizophrenia
ArchivedVerified|2 articles|2 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Vanda Pharmaceuticals developed Bysanti for bipolar disorder and schizophrenia
- •The FDA granted approval for Bysanti on February 21, 2026
- •Following the approval, Vanda's stock price increased significantly
- •Bysanti is intended to treat Bipolar I disorder and schizophrenia
What Could Happen If...
- ▸If Bysanti gains widespread adoption among patients and doctors Vanda could see increased sales and revenue, benefiting shareholders and expanding treatment options for patients
Market Exposure
StocksVanda Pharmaceuticals stockUpward Pressure
FDA approval of Bysanti increases investor confidence, leading to higher demand for Vanda shares
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Countries
Instruments
Source Coverage
FINANCE
2 articles
More coverage on this story
- Topic: US–China Economic Conflict
- More on United States of America
- More on Bysanti
- More on U.S. Food and Drug Administration
- More on Vanda Pharmaceuticals
Signals
Single-block coverage
Related Events
▸Ascendis Pharma gets FDA approval for navepegritide in achondroplasiaArchived▸COMPASS Pathways Gains FDA Rolling Review for Depression DrugArchived▸FDA approves higher-dose Wegovy for weight lossArchived▸Novo Nordisk and Hims & Hers plan obesity drug partnershipArchived▸Novo Nordisk eyes 15M Medicare patients with obesity treatments